Corporate Update


Hamburg, Germany - 18 March 2013: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that Dr Werner Lanthaler, Chief Executive Officer of Evotec, will resume his role as Chief Executive Officer of the Company with immediate effect after a period of leave due to health reasons.

Dr Flemming Ørnskov, Chairman of the Supervisory Board of Evotec AG, commented: 'The board is delighted to welcome back Dr Lanthaler to resume his leadership of Evotec and to continue to drive the growth of the Company through Action Plan 2016. The board would also like to thank the Management Team of Colin Bond, Dr Cord Dohrmann and Dr Mario Polywka for managing the company in Dr Lanthaler's absence.'


Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.